论文部分内容阅读
目的:评价并探讨坦索罗辛(Tamsulosin,Harnal)治疗前列腺癌伴发下尿路症状(LUTS)的临床疗效及治疗的安全性。方法:2009年1月～2010年10月,收治存在LUTS、血压正常且国际前列腺症状评分(IP-SS)均在20分以上的晚期前列腺癌患者76例,随机分为治疗组和对照组,均进行最大限度雄激素阻断治疗(MAB),同时治疗组联合应用超选择性α1A受体阻滞剂进行治疗。结果:治疗后4周和8周,治疗组的IPSS、生活质量指数评分、最大尿流率、前列腺体积、剩余尿量均较对照组有显著性改善(P<0.05),血压变化的差异无统计学意义(P>0.05)。治疗4周与8周比较无显著性差异(P>0.05)。结论:MAB治疗可延长晚期前列腺癌患者的无进展生存期,而坦索罗辛可有效改善晚期前列腺癌患者下尿路症状,提高生活质量,且不良反应甚微。
Objective: To evaluate the clinical efficacy and safety of Tamsulosin (Harnal) in the treatment of lower urinary tract symptoms (LUTS) associated with prostate cancer. Methods: From January 2009 to October 2010, 76 patients with advanced prostate cancer who had LUTS, normal blood pressure and IP-SS scores above 20 were randomly divided into treatment group and control group, All patients were treated with maximal androgen blockade (MAB), while the treatment group was treated with super selective α1A receptor blocker. Results: After 4 and 8 weeks of treatment, the IPSS, QOL, maximum uroflow rate, prostate volume and residual urine volume of the treatment group were significantly improved compared with the control group (P <0.05), no difference in blood pressure was found Statistical significance (P> 0.05). There was no significant difference between 4 weeks and 8 weeks treatment (P> 0.05). Conclusion: MAB treatment can prolong the progression-free survival of patients with advanced prostate cancer, while tamsulosin can effectively improve the lower urinary tract symptoms and improve the quality of life in patients with advanced prostate cancer with little adverse reaction.